参附注射液联合左旋多巴对帕金森病小鼠黑质组织形态及酪氨酸羟化酶水平的影响
摘要
目的研究参附注射液联合左旋多巴对帕金森病小鼠黑质组织形态及酪氨酸羟化酶水平的影响。方法 1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)腹腔注射制备帕金森病小鼠模型,分别给予左旋多巴、参附注射液、参附注射液+左旋多巴14 d后,检测小鼠神经行为学,ELISA法检测血液及脑组织中酪氨酸羟化酶(TH)水平,HE染色观察脑组织黑质区神经元,免疫组化染色、Western blot法检测脑组织黑质区TH蛋白表达。结果参附注射液可显著缩短爬杆时间,增加悬挂能力评分,提高TH水平及蛋白表达(P<0.05,P<0.01),联合左旋多巴应用时上述指标改善更明显(P<0.05,P<0.01)。结论参附注射液对帕金森病小鼠有神经保护作用,联合左旋多巴时效果更强。
引文
[1] Fernandez H H.2015 update on parkinson disease[J].Cleveland Clin J Med,2015,82(9):563-568.
[2] Mullin S,Schapira A H.Pathogenic mechanisms of neurodegeneration in Parkinson disease[J].Neurol Clin,2015,33(1):1-17.
[3] Nagatsu T,Nagatsu I.Tyrosine hydroxylase (TH),its cofactor tetrahydrobiopterin (BH4),other catecholamine-related enzymes,and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD):historical overview and future prospects[J].J Neural Transm (Vienna),2016,123(11):1255-1278.
[4] Zhu Y,Zhang J,Zeng Y.Overview of tyrosine hydroxylase in Parkinson’s disease[J].CNS Neurol Disord Drug Targets,2012,11(4):350-358.
[5] LeWitt P A.Levodopa therapy for Parkinson’s disease:pharmacokinetics and pharmacodynamics[J].Mov Disord,2015,30(1):64-72.
[6] Hu X W,Qin S M,Li D,et al.Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease:a meta-analysis[J].Acta Neurol Scand,2013,128(2):73-82.
[7] 任宝龙,张振帅,赵晓燕,等.左旋多巴治疗帕金森病的副作用探讨[J].卫生职业教育,2015,33(7):153-154.
[8] 杜婷,孙荣进,田华,等.参附注射液的药效学及作用机制研究进展[J].中国药师,2013,16(11):1732-1734.
[9] 刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[10] Jost W H.Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration[J].Expert Opin Drug Saf,2014,13(4):447-458.
[11] Smeyne M,Smeyne R J.Glutathione metabolism and Parkinson’s disease[J].Free Radic Biol Med,2013,62(1):13-25.
[12] 王慧新.帕金森病的中医治疗[J].吉林中医药,2015,35(8):791-793.
[13] 吴亚丹,梁培日,龙登毅,等.银杏平颤方对帕金森病模型小鼠多巴胺神经元丢失及其凋亡的影响[J].中国组织工程研究,2016,20(49):7327-7333.
[14] 杨莎莎,覃威,陈诗雅,等.肉苁蓉对帕金森病模型大鼠行为学及海马组织干细胞增殖相关蛋白表达的影响[J].康复学报,2016,26(6):24-27,33.
[15] 杨靖,李霖,谢雁鸣,等.参附注射液治疗冠心病临床用药方案实效研究[J].中国中药杂志,2013,38(18):3099-3103.
[16] 王卫霞,王巍,陈可冀.人参皂苷对动物脑神经保护作用及其机理研究进展[J].中国中西医结合杂志,2005,25(1):89-93.
[17] 孙莹莹,刘玥,陈可冀.人参皂苷的心血管药理效应:进展与思考[J].中国科学:生命科学,2016,46(6):771-778.
[2] Mullin S,Schapira A H.Pathogenic mechanisms of neurodegeneration in Parkinson disease[J].Neurol Clin,2015,33(1):1-17.
[3] Nagatsu T,Nagatsu I.Tyrosine hydroxylase (TH),its cofactor tetrahydrobiopterin (BH4),other catecholamine-related enzymes,and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD):historical overview and future prospects[J].J Neural Transm (Vienna),2016,123(11):1255-1278.
[4] Zhu Y,Zhang J,Zeng Y.Overview of tyrosine hydroxylase in Parkinson’s disease[J].CNS Neurol Disord Drug Targets,2012,11(4):350-358.
[5] LeWitt P A.Levodopa therapy for Parkinson’s disease:pharmacokinetics and pharmacodynamics[J].Mov Disord,2015,30(1):64-72.
[6] Hu X W,Qin S M,Li D,et al.Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease:a meta-analysis[J].Acta Neurol Scand,2013,128(2):73-82.
[7] 任宝龙,张振帅,赵晓燕,等.左旋多巴治疗帕金森病的副作用探讨[J].卫生职业教育,2015,33(7):153-154.
[8] 杜婷,孙荣进,田华,等.参附注射液的药效学及作用机制研究进展[J].中国药师,2013,16(11):1732-1734.
[9] 刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[10] Jost W H.Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration[J].Expert Opin Drug Saf,2014,13(4):447-458.
[11] Smeyne M,Smeyne R J.Glutathione metabolism and Parkinson’s disease[J].Free Radic Biol Med,2013,62(1):13-25.
[12] 王慧新.帕金森病的中医治疗[J].吉林中医药,2015,35(8):791-793.
[13] 吴亚丹,梁培日,龙登毅,等.银杏平颤方对帕金森病模型小鼠多巴胺神经元丢失及其凋亡的影响[J].中国组织工程研究,2016,20(49):7327-7333.
[14] 杨莎莎,覃威,陈诗雅,等.肉苁蓉对帕金森病模型大鼠行为学及海马组织干细胞增殖相关蛋白表达的影响[J].康复学报,2016,26(6):24-27,33.
[15] 杨靖,李霖,谢雁鸣,等.参附注射液治疗冠心病临床用药方案实效研究[J].中国中药杂志,2013,38(18):3099-3103.
[16] 王卫霞,王巍,陈可冀.人参皂苷对动物脑神经保护作用及其机理研究进展[J].中国中西医结合杂志,2005,25(1):89-93.
[17] 孙莹莹,刘玥,陈可冀.人参皂苷的心血管药理效应:进展与思考[J].中国科学:生命科学,2016,46(6):771-778.